In this episode, Dennis Walker is joined by Dr. Sam Zand and Derek Du Chesne, co-founders of Better U, to share the story of how they are helping to transform the narrative around seeking out mental health treatments, and to discuss how the stigma around mental health is being eradicated and replaced with a culture of self-love and acceptance.
Psychedelic News Surge: Massachusetts’ Plant Medicine Dive, Kentucky’s Ibogaine Initiative, Pain-Relieving Potential, and Ketamine’s Pediatric Promise
Chris works alongside companies to develop plant-based food and medicinal products, helping turn them into market successes. He has conducted medicinal plant research and sustainable botanical sourcing in over 45 countries, and has been featured on a number of platforms such as The New York Times, The Dr. Oz Show, Business Insider, CNN, VICE, and much more.
Field Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.
Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.
HAVN VS. Mindmed – Whose Cluster Headache Treatment Is Better?
Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our “This Week In Psychedelic Stocks” segment.
In light of HAVN’s recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore.
HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.
Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020.
The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) .
https://havnlife.com/
CSE: HAVN | OTC: HAVLF | FRA: 5NP
#HAVN #HAVNLifeSciences #Mindmed
![This Week in Psychedelic Stocks [Big UPDATES ON MMEDF, CMPS, FTRPF, and ATAI]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-33-600x338.jpeg)
Hello Psychedelic Investors! In this new segment entitled “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF), Compass Pathways (CMPS), Atai Life Sciences, and Field Trip Health (FTRPF/ FTRP).
We will cover the latest developments in the field writ large,
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Time Stamps
0:00 – Intro
0:56 – California Legalizing Psychedelics?
2:09 – Texas Legalizing Psychedelics?
3:33 – STOP LICKING TOADS DUDE
4:05 – MindMed Stock Updates (MMED / MMEDF)
9:13 – Compass Pathways Stock Updates (CMPS)
13:25 – Atai Life Sciences Update
17:05 – Field Trip Health Stock Updates (FTRPF/ FTRP)
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
